About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Division of Medical Oncology
›
top-articles
Division of Medical Oncology
60
(top 2%)
papers
2.5K
(top 1%)
citations
23
(top 1%)
h
-index
51
(top 1%)
g
-index
66
all documents
2.7K
doc citations
969
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
Journal of the National Comprehensive Cancer Network: JNCCN
2020
401
2
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
Journal of Clinical Oncology
2006
357
3
Treatment of metastatic melanoma: an overview
Oncology
2009
297
4
Interprofessional Communication Skills Training for Serious Illness: Evaluation of a Small-Group, Simulated Patient Intervention
Journal of Palliative Medicine
2014
116
5
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults ≥ 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
Journal of Clinical Oncology
2007
112
6
Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
Breast Cancer Research and Treatment
2007
97
7
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
Annals of Oncology
2015
95
8
Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab
Archives of Dermatology
2007
92
9
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL
Blood Advances
2019
92
10
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
Breast Cancer Research and Treatment
2010
90
11
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
Leukemia
2010
87
12
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy
Blood
2017
68
13
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Nature Medicine
2021
65
14
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
Leukemia
2008
58
15
Identifying Elements of ICU Care That Families Report as Important But Unsatisfactory
Chest
2012
52
16
Discussing Religion and Spirituality Is an Advanced Communication Skill: An Exploratory Structural Equation Model of Physician Trainee Self-Ratings
Journal of Palliative Medicine
2012
49
17
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
European Urology Oncology
2021
39
18
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
Future Oncology
2021
39
19
Advances in molecular imaging for breast cancer detection and characterization
Breast Cancer Research
2012
32
20
Self-Assessment Scores Improve After Simulation-Based Palliative Care Communication Skill Workshops
American Journal of Hospice and Palliative Medicine
2018
32
21
Medullary Thyroid Cancer: Options for Systemic Therapy of Metastatic Disease?
Journal of Clinical Oncology
2006
30
22
Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care
Seminars in Hematology
2018
27
23
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500)
American Journal of Hematology
2007
26
24
No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families
Breast Cancer Research and Treatment
2011
26
25
Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience
Cancer Treatment and Research Communications
2021
24
26
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
Annals of Translational Medicine
2021
23
27
Positron emission tomography imaging as a cancer biomarker
Expert Review of Molecular Diagnostics
2007
21
28
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Cancer Immunology, Immunotherapy
2019
21
29
Test–Retest Reproducibility of
18
F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network
Journal of Nuclear Medicine
2019
21
30
18
F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer
Journal of Nuclear Medicine
2021
20
31
FDG PET-CT in follicular lymphoma: a case-based evidence review
Blood
2015
19
32
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Annals of Oncology
2021
19
33
Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy
Cancers
2022
18
34
Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes
Bladder Cancer
2020
16
35
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study
Urologic Oncology: Seminars and Original Investigations
2018
15
36
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Clinical Cancer Research
2023
14
37
Association between Physician Trainee Self-Assessments in Discussing Religion and Spirituality and Their Patients' Reports
Journal of Palliative Medicine
2014
12
38
Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis
Clinical Lung Cancer
2020
11
39
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
Breast Cancer Research
2021
11
40
Indications for Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in the Genomic Era
American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting
2014
9
41
Monoclonal antibodies conjugated with radioisotopes for the treatment of non-Hodgkin's lymphoma
Seminars in Oncology Nursing
2002
7
42
Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes
Clinical Genitourinary Cancer
2022
7
43
Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics
European Urology Oncology
2022
6
44
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer
Urologic Oncology: Seminars and Original Investigations
2021
6
45
A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)
Annals of Oncology
2016
5
46
A digital health intervention to improve nutrition and physical activity in breast cancer survivors: Rationale and design of the Cook and Move for Your Life pilot and feasibility randomized controlled trial
Contemporary Clinical Trials
2022
5
47
A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma
Leukemia and Lymphoma
2018
4
48
Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti–PD‐1 Therapy
Laryngoscope
2019
4
49
Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
Lancet Oncology, The
2021
4
50
Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis
Cancer Research
2022
4
site/software ©
exaly
; All materials licenced under
CC by-SA
.